Cited by 39Alzheimer's disease research and treatmentsParkinson's Disease Mechanisms and TreatmentsProtein purification and stability

C-Phycocyanin from Spirulina Inhibits α-Synuclein and Amyloid-β Fibril Formation but Not Amorphous Aggregation

Liu, Yanqin, Jovcevski, Blagojce, Pukala, Tara L.·2019·Journal of Natural Products

Abstract

Proteinopathies including cataracts and neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, are characterized by a series of aberrant protein folding events, resulting in amorphous aggregate or amyloid fibril formation. In the latter case, research has heavily focused on the development of small-molecule inhibitors with limited success during clinical trials. However, very few studies have focused on utilizing exogenous proteins as potential aggregation inhibitors. C-Phycocyanin, derived from Spirulina sp., has been known to exert anti-inflammatory properties; however, the ability of C-phycocyanin to inhibit protein aggregation has yet to be investigated. We have demonstrated that C-phycocyanin is an effective inhibitor of A53Tα-synuclein at extremely low substoichiometric ratios (200-fold excess of α-synuclein) and Aβ40/42 fibril formation. However, C-phycocyanin is relatively ineffective in inhibiting the reduction-induced amorphous aggregation of ADH and heat-induced aggregation of catalase. In addition, 2D NMR, ion mobility-mass spectrometry, and analytical-SEC demonstrate that the interaction between C-phycocyanin and α-synuclein is through nonstable interactions, indicating that transient interactions are likely to be responsible for preventing fibril formation. Overall, this work highlights how biomolecules from natural sources could be used to aid in the development of therapeutics to combat protein misfolding diseases.

Integrity signals

Registry

Crossref · 10.1021/acs.jnatprod.8b00610

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • C-PC proved to be an effective inhibitor of A53Tα-Syn and Aβ40/42 fibril formation.

    “Interestingly, C-PC proved to be an effective inhibitor of A53Tα-Syn and Aβ40/42 fibril formation.”

    From Beneficial Effects of Spirulina Consumption on Brain Health (2022) · cites this paper as [118]

  • C-PC and α-Syn interact through unstable interactions, indicating that transient interactions can hinder fibril formation.

    “C-PC and α-Syn interact through unstable interactions, indicating that perhaps transient interactions can hinder fibril formation [118].”

    From Beneficial Effects of Spirulina Consumption on Brain Health (2022) · cites this paper as [118]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Liu, Y., Jovcevski, B., & Pukala, T. L.
Affiliations
  • Hebei Agricultural University (CN)
  • The School of Physical Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia
  • The University of Adelaide (AU)
Corresponding author
Pukala, Tara L.
Venue
Journal of Natural Products
Published
2019-01-08
Volume
82
Issue
1
Pages
66-73
ISSN
  • 0163-3864 (ISSN-L)
  • 1520-6025
OpenAlex
W2909628053
Cited by
39
References
45
Citations by year
2026: 4 · 2025: 4 · 2024: 7 · 2023: 6 · 2022: 8 · 2021: 3 · 2020: 6 · 2019: 1
FWCI
3.09
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Natural Products (publishedVersion)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Funders
  • Department of Education and Training (DP1093143, DP170102033)
  • Hebei Agricultural University (Start-up Grant ZD201624)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
Keywords
C-phycocyanin, Spirulina, alpha-synuclein, amyloid-beta, protein aggregation inhibition, fibril formation, A53T alpha-synuclein, proteinopathies, Alzheimer's disease, Parkinson's disease, cataract, transient protein interactions
MeSH terms
Amyloid, Peptide Fragments, Phycocyanin, Amyloid beta-Peptides, alpha-Synuclein, Spirulina, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review